Kane Biotech Announces Third Quarter 2024 Financial Results
28. November 2024 16:15 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its third quarter 2024 financial results. ...
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
27. November 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech” or “Kane”) announces today that BioStem Technologies Inc....
Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024
21. November 2024 16:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will release its third quarter 2024 financial results after market close on...
Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel
14. November 2024 13:10 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its...
Kane Biotech Provides Investor Update Following FB Dermatology Acquisition Announcement
14. November 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech”) announces today that President & CEO, Marc Edwards and Dr....
Kane Biotech Announces Agreement to Acquire FB Dermatology
12. November 2024 13:08 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech”) announces today that it has entered into a binding term sheet (the...
Kane Biotech Announces Donation of revyve™ Antimicrobial Wound Gel to Ukraine
23. Oktober 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it is donating 2,000 ounces of revyve™ Antimicrobial Wound...
Kane Biotech Announces Exclusive Distribution Agreement With XSONX
17. Oktober 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has signed an exclusive five year distribution...
Kane Biotech to Participate in a Multinational Corporate Collaboration Project
03. Oktober 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services and up to...
Kane Biotech Announces Attendance at Upcoming Wound Care Conferences
26. September 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the Company will be showcasing its revyve™...